These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31226721)

  • 1. Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial.
    Schüpke S; Hein-Rothweiler R; Mayer K; Janisch M; Sibbing D; Ndrepepa G; Hilz R; Laugwitz KL; Bernlochner I; Gschwendtner S; Kupka D; Gori T; Zeiher AM; Schunkert H; Massberg S; Kastrati A;
    Thromb Haemost; 2019 Sep; 119(9):1539-1545. PubMed ID: 31226721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial.
    Mayer K; Hein-Rothweiler R; Schüpke S; Janisch M; Bernlochner I; Ndrepepa G; Sibbing D; Gori T; Borst O; Holdenrieder S; Kupka D; Petzold T; Bradaric C; Okrojek R; Leistner DM; Trippel TD; Münzel T; Landmesser U; Pieske B; Zeiher AM; Gawaz MP; Hapfelmeier A; Laugwitz KL; Schunkert H; Kastrati A; Massberg S
    JAMA Cardiol; 2021 Jul; 6(7):753-761. PubMed ID: 33787834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
    Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
    Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
    J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
    Geisler T; Müller K; Karathanos A; Bocksch W; Gawaz M; Deliargyris E; Bernstein D; Lincoff AM; Mehran R; Dangas G; Stone GW
    EuroIntervention; 2014 May; 10(1):97-104. PubMed ID: 24048204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention.
    Busch G; Steppich B; Sibbing D; Braun SL; Stein A; Groha P; Schömig A; Kastrati A; von Beckerath N; Ott I
    Thromb Haemost; 2009 Feb; 101(2):340-4. PubMed ID: 19190819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Multicenter Randomized Phase II Trial.
    Uphaus T; Richards T; Weimar C; Neugebauer H; Poli S; Weissenborn K; Imray C; Michalski D; Rashid H; Loftus I; Rummey C; Ritter M; Hauser TK; Münch G; Gröschel K; Poppert H
    Stroke; 2022 Sep; 53(9):2718-2729. PubMed ID: 35695006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
    Mehran R; Pocock S; Nikolsky E; Dangas GD; Clayton T; Claessen BE; Caixeta A; Feit F; Manoukian SV; White H; Bertrand M; Ohman EM; Parise H; Lansky AJ; Lincoff AM; Stone GW
    JACC Cardiovasc Interv; 2011 Jun; 4(6):654-64. PubMed ID: 21700252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.
    Zheng YY; Wu TT; Yang Y; Hou XG; Gao Y; Chen Y; Yang YN; Li XM; Ma X; Ma YT; Xie X
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):211-221. PubMed ID: 31603191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
    JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
    J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial).
    Goto K; Lansky AJ; Ng VG; Pietras C; Nargileci E; Mehran R; Parise H; Feit F; Ohman EM; White HD; Bertrand ME; Desmet W; Hamon M; Stone GW
    Am J Cardiol; 2014 Dec; 114(11):1638-45. PubMed ID: 25312637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome.
    Frere C; Laine M; Lemesle G; Morange PE; Paganelli F; Dignat-George F; Resseguier N; Guieu R; Camoin-Jau L; Bonello L
    Platelets; 2019; 30(1):105-111. PubMed ID: 29172822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention.
    Deshpande NV; Pratiti R; Admane P; Mukherjee D; Mardikar HM
    Indian Heart J; 2012; 64(5):444-8. PubMed ID: 23102380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Approaches for Preventing or Limiting Events (NAPLES III) Trial: randomised comparison of bivalirudin versus unfractionated heparin in patients at high risk of bleeding undergoing elective coronary stenting throught the femoral approach. rationale and design.
    Briguori C; Visconti G; Focaccio A; Donahue M; Golia B; Selvetella L; Ricciarelli B
    Cardiovasc Drugs Ther; 2014 Jun; 28(3):273-9. PubMed ID: 24781074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.
    Shah A; Feldman DN
    Vasc Health Risk Manag; 2012; 8():115-23. PubMed ID: 22399856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
    Gurm HS; Smith DE; Chetcuti SJ; Share D; Khanal S; Riba A; Carter AJ; Lalonde T; Kline-Rogers E; O'Donnell M; O'Neill W; Safian R; Moscucci M;
    J Interv Cardiol; 2007 Jun; 20(3):197-203. PubMed ID: 17524111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
    Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
    Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.